Advanced search
Publication Cover
Leukemia & Lymphoma Volume 64, 2023 - Issue 3
Submit an article Journal homepage
231
Views
2
CrossRef citations to date
0
Altmetric
Letters to the Editor

Sudden lymphoid blast crisis after tyrosine kinase inhibitor discontinuation in chronic phase chronic myeloid leukemia: cautionary tales for appropriate molecular monitoring

Alex BatallerDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USAORCID Iconhttps://orcid.org/0000-0002-6085-2745View further author information
ORCID Icon,
Fadi G. HaddadDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Ghayas C. IssaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USAORCID Iconhttps://orcid.org/0000-0002-4339-8683View further author information
ORCID Icon,
Koji SasakiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USAORCID Iconhttps://orcid.org/0000-0002-9140-0610View further author information
ORCID Icon,
Elias JabbourDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Gautam BorthakurDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USAORCID Iconhttps://orcid.org/0000-0001-7679-6453View further author information
ORCID Icon,
Alessandra FerrajoliDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
&
Nicholas J. ShortDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-2983-2738View further author information
ORCID Icon show all
Pages 746-749 | Received 25 Oct 2022, Accepted 30 Dec 2022, Published online: 19 Jan 2023

References

  • Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring. Am J Hematol. 2022;97(9):1236–1256.
  • Chereda B, Melo J V Natural course and biology of CML. Ann Hematol. 2015;94(S2):107–121.
  • Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 2020 34:4. 2020;34(4):966–984.
  • Ross DM, Branford S, Seymour JF, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122(4):515–522.
  • Saussele S, Richter J, Guilhot J, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018;19(6):747–757.
  • Mahon FX, Réa D, Guilhot J, Intergroupe Français des Leucémies Myéloïdes Chroniques, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre stop imatinib (STIM) trial. Lancet Oncol. 2010;11(11):1029–1035.
  • Haddad FG, Sasaki K, Issa GC, et al. Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors. Am J Hematol. 2022;97(7):856–864.
  • Atallah E, Schiffer CA. Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom? Haematologica. 2020;105(12):2738–2745.
  • Senapati J, Jabbour E, Kantarjian H, et al. Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia. Leukemia 2022. Epub ahead of print.
  • Perrotti D, Jamieson C, Goldman J, et al. Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest. 2010;120(7):2254–2264.
  • Qiao J, Liang C, Zhao D, et al. Spred1 deficit promotes treatment resistance and transformation of chronic phase CML. Leukemia. 2022;36(2):492–506.
  • Lovat F, Gasparini P, Nigita G, et al. Loss of expression of both miR-15/16 loci in CML transition to blast crisis. Proc Natl Acad Sci USA. 2021;118(11):e2101566118.
  • Ilander M, Olsson-Strömberg U, Schlums H, et al. Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia. Leukemia. 2017 31:52017;31(5):1108–1116.
  • Vigón L, Luna A, Galán M, et al. Identification of immunological parameters as predictive biomarkers of relapse in patients with chronic myeloid leukemia on Treatment-Free remission. Journal of Clinical Medicine 2021. 2020;10(1):42. Vol. 10, Page 42.
  • Miao YR, Liu W, Zhong Z, et al. Case report: multi-Omics analysis and CAR-T treatment of a chronic myeloid leukemia blast crisis case 5 years after the discontinuation of TKI. Front Oncol. 2021;11:3604.
  • Rousselot P, Charbonnier A, Cony-Makhoul P, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol. 2014;32(5):424–430.
  • Papalexandri A, Saloum R, Touloumenidou T, et al. Blast crisis of CML after TKI discontinuation in a patient with previous stable deep molecular response: is it safe to stop? Hemasphere. 2018;2(6):e157.
  • Dulucq S, Hayette S, Cayuela J-M, et al. Onset of blast crisis in chronic myeloid leukemia patients in treatment-free remission. Haematologica. 2022;107(12):2944–2949.
  • Willis SG, Lange T, Demehri S, et al. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood. 2005;106(6):2128–2137.
  • Morita K, Kantarjian HM, Sasaki K, et al. Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and philadelphia chromosome–positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib. Cancer. 2021;127(15):2641–2647.
  • Radujkovic A, Dietrich S, Blok H-J, et al. Allogeneic stem cell transplantation for blast crisis chronic myeloid leukemia in the era of tyrosine kinase inhibitors: a retrospective study by the EBMT chronic malignancies working party. Biol Blood Marrow Transplant. 2019;25(10):2008–2016.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.